ATOS Stock Overview
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Atossa Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.42 |
| 52 Week High | US$2.31 |
| 52 Week Low | US$0.59 |
| Beta | 1.24 |
| 1 Month Change | -8.39% |
| 3 Month Change | 73.17% |
| 1 Year Change | 98.32% |
| 3 Year Change | -18.39% |
| 5 Year Change | -55.63% |
| Change since IPO | -99.84% |
Recent News & Updates
Recent updates
Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans
Mar 07
We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate
Nov 08Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth
Apr 26We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate
Jan 09Atossa Therapeutics: Still Gets An 'Incomplete' Rating
Oct 11We're Hopeful That Atossa Therapeutics (NASDAQ:ATOS) Will Use Its Cash Wisely
Sep 25Atossa Therapeutics GAAP EPS of -$0.05
Aug 08Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth
May 12A First Assessment On Atossa Therapeutics
Dec 10We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate
Dec 02Atossa Therapeutics: Diversification Into COVID Makes Sense In A Variants World
Sep 22Atossa Therapeutics (NASDAQ:ATOS) Is In A Strong Position To Grow Its Business
Jul 17Atossa Therapeutics: Hope Springs Eternal
Jun 30Atossa Therapeutics to be included in the Russell 2000, 3000 indexes
Jun 16Atossa reaches a two-year high ahead of data readout for breast cancer therapy
Jun 07Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans
Apr 02Atossa updates on single-patient study for Endoxifen
Feb 04Atossa halts Endoxifen breast cancer study after positive data
Feb 02Atossa Therapeutics prices ~$25M direct offering, stock -23% PM
Jan 06Atossa Therapeutics prices $14M registered direct offering
Dec 17We're A Little Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate
Dec 10
Atossa Therapeutics plummets 38% after it raises $20M in public offering
Dec 09Atossa Therapeutics EPS in-line
Nov 13Safety data on COVID-19 nasal spray fails to lift Atossa, down 6%
Nov 10Shareholder Returns
| ATOS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -19.8% | -4.2% | -3.7% |
| 1Y | 98.3% | -2.0% | 20.5% |
Return vs Industry: ATOS exceeded the US Biotechs industry which returned -2% over the past year.
Return vs Market: ATOS exceeded the US Market which returned 20.5% over the past year.
Price Volatility
| ATOS volatility | |
|---|---|
| ATOS Average Weekly Movement | 13.2% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ATOS's share price has been volatile over the past 3 months.
Volatility Over Time: ATOS's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 12 | Steve Quay | atossatherapeutics.com |
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company’s lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment.
Atossa Therapeutics, Inc. Fundamentals Summary
| ATOS fundamental statistics | |
|---|---|
| Market cap | US$177.93m |
| Earnings (TTM) | -US$30.09m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.9x
P/E RatioIs ATOS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATOS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$30.09m |
| Earnings | -US$30.09m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.24 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ATOS perform over the long term?
See historical performance and comparison